Profil
Mr. Pedro Gonzalez de Cosio is Co-Founder & Chief Executive Officer at Pharmakon Advisors LP.
Prior to co-founding Pharmakon Advisors in June 2009, Mr. Gonzalez de Cosio was a Director at Deutsche Bank Securities and a Vice President at JP Morgan Securities, Inc.
Mr. Gonzalez de Cosio received his MBA from INSEAD.
Postes actifs de Pedro Gonzalez de Cosio
| Sociétés | Poste | Début |
|---|---|---|
Pharmakon Advisors LP
Pharmakon Advisors LP Investment ManagersFinance Pharmakon Advisors is an investment manager of the BioPharma Credit funds. The firm invests in companies located in the US. It targets companies operating in the fields of life sciences sector. It provides debt financing with an investment size ranging from $35 - $500 million. | Directeur Général | 01/06/2009 |
Anciens postes connus de Pedro Gonzalez de Cosio
| Sociétés | Poste | Fin |
|---|---|---|
| DEUTSCHE BANK AG | Directeur/Membre du Conseil | 01/06/2009 |
| JPMORGAN CHASE & CO. | Private Equity Investor | 01/05/2005 |
Formation de Pedro Gonzalez de Cosio
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Deutsche Bank AG
Deutsche Bank AG Investment Banks/BrokersFinance Provides investment and corporate banking & asset management services | Finance |
JPMorgan Chase & Co.
JPMorgan Chase & Co. Major BanksFinance Provides banking, asset management, investment banking, credit card and mortgage services | Finance |
INSEAD
INSEAD Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of San Diego
University of San Diego Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pharmakon Advisors LP
Pharmakon Advisors LP Investment ManagersFinance Pharmakon Advisors is an investment manager of the BioPharma Credit funds. The firm invests in companies located in the US. It targets companies operating in the fields of life sciences sector. It provides debt financing with an investment size ranging from $35 - $500 million. | Finance |
















